-
公开(公告)号：WO2022092181A1
公开(公告)日：2022-05-05
申请号：PCT/JP2021/039754
申请日：2021-10-28
Applicant: 東洋紡株式会社 , 国立大学法人富山大学
IPC: C12N15/13 , A61K31/7088 , A61K36/06 , A61K39/395 , A61P31/14 , C07K16/10 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/62 , C12P21/08 , G01N33/53 , G01N33/543
Abstract: SARS CoV2のNタンパク質のNTD又はCTDに特異的に結合する抗体又はその断片、及びその用途を提供する。配列番号1又は2で示されるアミノ酸配列に特異的に結合する抗体又はその断片が開示される。
-
公开(公告)号：WO2022087393A1
公开(公告)日：2022-04-28
申请号：PCT/US2021/056225
申请日：2021-10-22
Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Inventor： MORAN, Thomas , KRAUS, Thomas , TORTORELLA, Domenico , DUTY, J. Andrew
Abstract: Provided herein are antibodies that bind to SARS-CoV-2 spike protein or a fragment thereof (e.g., receptor binding domain (RBD)), host cells for producing such antibodies, and kits comprising such antibodies. Also provided herein are compositions comprising antibodies that bind to SARS-CoV-2 spike protein or a fragment thereof (e.g., receptor binding domain) and methods of using such antibodies to diagnose, prevent or treat a SARS-CoV-2 infection, or COVID-19.
-
公开(公告)号：WO2022087316A1
公开(公告)日：2022-04-28
申请号：PCT/US2021/056116
申请日：2021-10-21
Applicant: LA JOLLA INSTITUTE FOR IMMUNOLOGY
Inventor： SAPHIRE, Erica Ollmann , HASTIE, Kathryn , LANDERAS-BUENO, Sara , HARKINS, Stephanie
Abstract: Compositions and methods are disclosed for diagnosing, treating, and/or preventing coronavirus infection and related pathologies. The compositions include antibodies having certain defined heavy and light chain sequences that recognize the coronavirus nucleoprotein or mutants thereof. In embodiments, the coronavirus is SAR-CoV-2.
-
公开(公告)号：WO2022082217A1
公开(公告)日：2022-04-21
申请号：PCT/US2021/071893
申请日：2021-10-14
Applicant: EUREKA THERAPEUTICS, INC.
Inventor： LIU, Cheng , ZHANG, Hongbing , YANG, Zhiyuan , XIANG, Jingyi , CUI, Ziyou , LIU, Jianying
IPC: A61K39/395 , A61K39/42 , A61K47/66 , C07K16/10 , A61P31/14
Abstract: The present application relates to compositions for preventing or treating viral and other microbial infections. In some embodiments, the present application provides chimeric proteins comprising a target-binding moiety that specifically binds to a pathogen that infects through a mucosa, and a positively charged mucoadhesive peptide fragment. Also provided are antibodies and constructs thereof that specifically binds to an S1 subunit of a spike protein of SARS-CoV-2. Compositions comprising the chimeric proteins, antibodies, or constructs described herein are useful for preventing or treating a microbial infection in an individual, such as a coronavirus infection.
-
公开(公告)号：WO2022079032A1
公开(公告)日：2022-04-21
申请号：PCT/EP2021/078184
申请日：2021-10-12
Applicant: UNIVERSITE DE LILLE , CENTRALE LILLE INSTITUT , UNIVERSITE POLYTECHNIQUE HAUTS-DE-FRANCE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , CENTRE HOSPITALIER UNIVERSITAIRE DE LILLE , UNIVERSITÉ D'AIX-MARSEILLE
Inventor： SZUNERITS, Sabine , ROUSSEL, Alain , CAMBILLAU, Christian , DEVOS, David , ENGELMAN, Ilka , ALIDJINOU, Enagnon Kazali
IPC: G01N33/569 , A61K39/42 , A61K39/44 , C07K16/087 , C07K16/10 , C07K2317/22 , C07K2317/567 , C07K2317/569 , G01N33/56983
Abstract: The present invention relates to methods for detecting a target in a sample using mutated nanobodies, wherein an amino acid present in the loop of the FR1 region of framework of the nanobodies is mutated to cysteine.
-
Patent Agency Ranking
公开(公告)号：WO2022077613A1
公开(公告)日：2022-04-21
申请号：PCT/CN2020/126206
申请日：2020-11-03
Applicant: 深圳市疾病预防控制中心
IPC: C07K14/165 , C07K16/10 , G01N33/68 , G01N33/569 , A61K39/215 , A61P31/14 , A61K39/12 , C07K14/005 , C07K2317/34 , C12N2770/20022 , C12N2770/20034 , G01N2333/165 , G01N2469/20 , G01N33/56983 , G01N33/6854
Abstract: 适用于生物学技术领域，提供了一种新型冠状病毒S蛋白的B细胞线性抗原表位、抗体、鉴定方法及应用，其中，所述S蛋白的B细胞线性抗原表位的氨基酸序列为如SEQ ID NO.104或SEQ ID NO.82所示，提供了全新的新型冠状病毒S蛋白的B细胞线性抗原表位，可以用于检测COVID-19患者血液中的特定抗体，也可以用于接种健康人群从而诱导产生特异性的抗体，从而为SARS-CoV-2疫苗设计、单克隆抗体研发以及抗体检测试剂盒的研发提供重要的抗原靶点。
-
公开(公告)号：WO2022075667A1
公开(公告)日：2022-04-14
申请号：PCT/KR2021/013511
申请日：2021-10-01
Applicant: 한양대학교 산학협력단
Abstract: 본 발명은 이황화 결합을 통해 안정성이 향상된 Ace2 변이체, 이를 이용한 Ace2-Fc 융합단백질 및 COVID-19 예방 또는 치료용 약학 조성물에 관한 것이다. 본 발명에 따르면, Ace2 단백질의 특정 위치의 잔기쌍을 시스테인으로 치환하여 이황화 결합을 도입함으로써, SARS-CoV-2 바이러스와의 결합 친화도가 높으면서 수용액 상태에서도 우수한 안정성을 나타내는 Ace2 단백질 변이체를 제공할 수 있다. 이에 따라, 본 발명의 안정화 Ace2 변이체를 SARS-CoV-2 감염질환인 COVID-19의 치료제에 적용하는 경우 보관 안정성, 체내 안정성 및 치료 효과를 모두 향상시킬 수 있다. 또한, SARS-CoV-2에 대한 수용체 유래의 아미노산 서열을 이용하므로, 다양한 변종 바이러스에도 효과적으로 작용할 수 있다.
-
公开(公告)号：WO2022071581A1
公开(公告)日：2022-04-07
申请号：PCT/JP2021/036446
申请日：2021-10-01
Applicant: 株式会社Ｅｐｓｉｌｏｎ Ｍｏｌｅｃｕｌａｒ Ｅｎｇｉｎｅｅｒｉｎｇ , 学校法人北里研究所 , 花王株式会社
Inventor： 正木 秀和 , 熊地 重文 , 米原 涼 , 松村 佑太 , 河野 響 , 東條 卓人 , 森本 拓也 , 片山 和彦 , 芳賀 慧 , 戸高 玲子 , 澤田 成史 , 高野 友美
IPC: C12N15/13 , A61K39/215 , A61P31/14 , C07K16/10 , C07K16/46
Abstract: ＳＡＲＳ－ＣｏＶ－２に結合するペプチド及びその利用法を提供する。 配列番号１～９のいずれかで示されるアミノ酸配列又は当該アミノ酸配列において少なくとも１つのアミノ酸が他のアミノ酸に置換されたアミノ酸配列からなるＣＤＲ３を含む構造ドメインを１つ以上有する、ＳＡＲＳ－ＣｏＶ－２に結合するペプチド。
-
公开(公告)号：WO2022068844A1
公开(公告)日：2022-04-07
申请号：PCT/CN2021/121534
申请日：2021-09-29
Applicant: VAZYME BIOTECH CO., LTD.
Inventor： CAO, Lin , LU, Bai , DOU, Yang , PAN, Jianfeng , XU, Lingjie , XU, Xiaoyu
Abstract: The present disclosure provides novel neutralizing antibody against spike protein of SARS-COV-2, and the antigen binding fragments thereof. Pharmaceutical composition and kits comprising the same, and the uses thereof are also provided.
-
公开(公告)号：WO2022067020A1
公开(公告)日：2022-03-31
申请号：PCT/US2021/051925
申请日：2021-09-24
Inventor： REGEV, Aviv , CHEN, Xun
IPC: C07K16/10
Abstract: The present invention discloses antibodies capable of binding to and neutralizing SARS-CoV-2 and variants thereof. The invention also discloses a cell-free antibody engineering platform capable of identifying antibodies that bind to specific target molecules and virus-neutralizing antibodies.
-
-
-
-
-
-
-
-
-
Search Results
2090
records
(took 0.03 seconds)
